NASDAQ:AMGNAmgen Stock Price, Forecast & News

$211.58

+6.17 (+3.00 %)

(As of 04/7/2020 08:13 AM ET)

Add

Compare

Today's Range

$206.85

Now: $211.58▼

$212.71

50-Day Range

$182.24

MA: $205.84▼

$223.48

52-Week Range

$166.30

Now: $211.58▼

$244.99

Volume3.68 million shs

Average Volume4.49 million shs

Market Capitalization$124.79 billion

P/E Ratio16.44

Dividend Yield3.12%

Beta0.9

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, and neuroscience. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, a pegylated protein to treat cancer patients; Prolia to treat postmenopausal women with osteoporosis; Aranesp to treat anemia; Xgeva for skeletal-related events prevention; Sensipar/Mimpara products to treat sHPT in chronic kidney disease; and EPOGEN to treat a lower-than-normal number of red blood cells. It also markets other products in various markets, including Kyprolis, Nplate, Vectibix, Repatha, NEUPOGEN, Parsabiv, Blincyto, Aimovig, Imlygic, Corlanor, Kanjintitm, and Amgevitatm. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaborative agreements with Novartis; UCB; Bayer HealthCare Pharmaceuticals Inc.; and DaVita Inc. Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California.

Beat the Market (BTM) Rank^™

3.3 Analyst's Opinion

Consensus Rating
Amgen has received a consensus rating of Buy. The company's average rating score is 2.54, and is based on 15 buy ratings, 10 hold ratings, and 1 sell rating.
Price Target Upside/Downside
According to analysts' consensus price target of $238.70, Amgen has a potential upside of 12.8% from its current price of $211.58.
Amount of Analyst Coverage
Amgen has been the subject of 19 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

3.0 Community Rank

Outperform Votes
Amgen has received 1,383 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Amgen has received 917 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Amgen has received 60.13% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Amgen and other stocks. Vote “Outperform” if you believe AMGN will outperform the S&P 500 over the long term. Vote “Underperform” if you believe AMGN will underperform the S&P 500 over the long term. You may vote once every thirty days.

4.2 Dividend Strength

Dividend Leadership
Amgen is a leading dividend payer. It pays a dividend yield of 3.12%, putting its dividend yield in the top 25% of dividend-paying stocks.
Dividend Growth
Amgen has been increasing its dividend for 9 years.
Dividend Coverage
The dividend payout ratio of Amgen is 43.18 %. This payout ratio is at a healthy, sustainable level, below 75%.
Dividend Sustainability
Based on earnings estimates, Amgen will have a dividend payout ratio of 37.91 % next year. This indicates that Amgen will be able to sustain or increase its dividend.

1.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Amgen insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,229,403.00 in company stock.
Percentage Held by Insiders
Only 0.25% of the stock of Amgen is held by insiders.
Percentage Held by Institutions
77.36% of the stock of Amgen is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6 Earnings and Valuation

Earnings Growth
Earnings for Amgen are expected to grow by 9.11% in the coming year, from $15.47 to $16.88 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Amgen is 16.44, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 10.77.
Price to Earnings Ratio vs. Sector
The P/E ratio of Amgen is 16.44, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 13.55.
Price to Earnings Growth Ratio
Amgen has a PEG Ratio of 1.39. PEG Ratios above 1 indicate that a company could be overvalued.
Price to Book Value per Share Ratio
Amgen has a P/B Ratio of 13.00. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Overall Beat the Market Rank^™

2.41 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Biological products, except diagnostic

Sub-IndustryBiotechnology

SectorMedical

Current SymbolNASDAQ:AMGN

Previous Symbol

CUSIP03116210

CIK318154

Webhttp://www.amgen.com/

Phone805-447-1000

Debt

Debt-to-Equity Ratio2.79

Current Ratio1.44

Quick Ratio1.16

Price-To-Earnings

Trailing P/E Ratio16.44

Forward P/E Ratio13.68

P/E Growth1.39

Sales & Book Value

Annual Sales$23.36 billion

Price / Sales5.34

Cash Flow$19.48 per share

Price / Cash Flow10.86

Book Value$16.28 per share

Price / Book13.00

Profitability

EPS (Most Recent Fiscal Year)$14.82

Net Income$7.84 billion

Net Margins33.57%

Return on Equity85.52%

Return on Assets14.89%

Miscellaneous

Employees23,400

Outstanding Shares589,810,000

Market Cap$124.79 billion

Next Earnings Date5/5/2020 (Estimated)

OptionableOptionable

Receive AMGN News and Ratings via Email

Sign-up to receive the latest news and ratings for AMGN and its competitors with MarketBeat's FREE daily newsletter.

Amgen (NASDAQ:AMGN) Frequently Asked Questions

How has Amgen's stock been impacted by COVID-19 (Coronavirus)?

Amgen's stock was trading at $198.65 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, AMGN stock has increased by 6.5% and is now trading at $211.58. View which stocks have been mosted impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Amgen?

26 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Amgen in the last year. There are currently 1 sell rating, 10 hold ratings and 15 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Amgen.

When is Amgen's next earnings date?

Amgen is scheduled to release its next quarterly earnings announcement on Tuesday, May 5th 2020. View our earnings forecast for Amgen.

How were Amgen's earnings last quarter?

Amgen, Inc. (NASDAQ:AMGN) announced its earnings results on Thursday, January, 30th. The medical research company reported $3.64 EPS for the quarter, beating the Zacks' consensus estimate of $3.47 by $0.17. The medical research company earned $6.20 billion during the quarter, compared to analysts' expectations of $6.04 billion. Amgen had a return on equity of 85.52% and a net margin of 33.57%. Amgen's quarterly revenue was down .5% on a year-over-year basis. During the same quarter last year, the business earned $3.42 EPS. View Amgen's earnings history.

How often does Amgen pay dividends? What is the dividend yield for Amgen?

Amgen declared a quarterly dividend on Wednesday, March 4th. Shareholders of record on Monday, May 18th will be given a dividend of $1.60 per share on Monday, June 8th. This represents a $6.40 annualized dividend and a yield of 3.02%. The ex-dividend date of this dividend is Friday, May 15th. View Amgen's dividend history.

What guidance has Amgen issued on next quarter's earnings?

Amgen issued an update on its FY20 earnings guidance on Thursday, January, 30th. The company provided earnings per share (EPS) guidance of $14.85-$15.60 for the period, compared to the Thomson Reuters consensus estimate of $16.10. The company issued revenue guidance of $25.0-$25.6 billion, compared to the consensus revenue estimate of $25.41 billion.

What price target have analysts set for AMGN?

26 analysts have issued 1-year price targets for Amgen's stock. Their forecasts range from $185.00 to $277.00. On average, they expect Amgen's share price to reach $238.70 in the next year. This suggests a possible upside of 12.8% from the stock's current price. View analysts' price targets for Amgen.

What are Wall Street analysts saying about Amgen stock?

Here are some recent quotes from research analysts about Amgen stock:

1. William Blair analysts commented, "We ultimately view the deal as positive for Amgen and a good fit for management’s strategy given the low-risk nature of the deal and immediate accretion." (8/30/2019)
2. Evercore ISI analysts commented, "We used a discount rate which is a function of cost of equity and cost of debt. Terminal growth rate estimates were used to derive future cash flows." (8/11/2019)
3. According to Zacks Investment Research, "While Amgen’s newer drugs — Prolia, Xgeva, Blincyto, Kyprolis — will drive sales, biosimilar and brand competition faced by its legacy drugs will create pressure on the top line in 2019. Meanwhile, uptake of key drug, Repatha has been slow due to payer restrictions. However, Amgen is progressing well with its pipeline and approval of Aimovig was a huge boost. In the past five years, Amgen has launched nine products, including two in new therapeutic areas. Amgen boasts a strong biosimilars pipeline, which could be an important long-term growth driver for the company. Amgen’s restructuring plan is making it leaner and more cost efficient. Lower taxes and share buybacks should provide some support to the bottom line. Amgen’s shares have underperformed the industry this year so far. Estimates have declined lightly ahead of the Q1 earnings release. Amgen has a positive record of earnings surprises in recent quarters." (4/15/2019)
4. Mizuho analysts commented, "We think the peak sales potential of Vascepa is underappreciated. Therefore, upward earnings revisions to levels not reflected in FactSet consensus expectations should drive AMRN shares higher. Valuation Summary We continue to use a blend of DCF and multiples (EV/EBITDA) analysis to get to our 12-month price target of $35." (4/12/2019)

Has Amgen been receiving favorable news coverage?

Headlines about AMGN stock have trended very negative on Tuesday, InfoTrie Sentiment reports. InfoTrie rates the sentiment of media coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Amgen earned a coverage optimism score of -3.3 on InfoTrie's scale. They also assigned media stories about the medical research company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the company's share price in the near term. View the latest news aboutAmgen.

Who are some of Amgen's key competitors?

Some companies that are related to Amgen include Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Seattle Genetics (SGEN), Alexion Pharmaceuticals (ALXN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS), Repligen (RGEN) and Exelixis (EXEL).

What other stocks do shareholders of Amgen own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Amgen investors own include Johnson & Johnson (JNJ), Walt Disney (DIS), Alibaba Group (BABA), NVIDIA (NVDA), Intel (INTC), AT&T (T), Cisco Systems (CSCO), Pfizer (PFE), Gilead Sciences (GILD) and JPMorgan Chase & Co. (JPM).

Who are Amgen's key executives?

Amgen's management team includes the following people:

Mr. Robert A. Bradway, Chairman, CEO & Pres (Age 56)
Mr. David W. Meline, Exec. VP & CFO (Age 62)
Mr. Jonathan P. Graham, Sr. VP, Gen. Counsel & Sec. (Age 58)
Dr. David M. Reese M.D., Exec. VP of R&D (Age 56)
Mr. Murdo Gordon, Exec. VP of Global Commercial Operations (Age 52)

What is Amgen's stock symbol?

Amgen trades on the NASDAQ under the ticker symbol "AMGN."

Who are Amgen's major shareholders?

Amgen's stock is owned by a number of retail and institutional investors. Top institutional shareholders include State of Alaska Department of Revenue (0.02%), Cullinan Associates Inc. (0.01%), American National Bank (0.00%), McGuire Investment Group LLC (0.00%), Thomasville National Bank (0.00%) and Burns J W & Co. Inc. NY (0.00%). Company insiders that own Amgen stock include Cynthia M Patton, David Piacquad, David W Meline, Jonathan P Graham, R Sanders Williams, Ronald D Sugar, Sean E Harper and Tyler Jacks. View institutional ownership trends for Amgen.

Which major investors are selling Amgen stock?

AMGN stock was sold by a variety of institutional investors in the last quarter, including Cullinan Associates Inc., Pensionfund DSM Netherlands, IMS Capital Management, Thomasville National Bank, Fulcrum Equity Management, Triangle Securities Wealth Management, Park National Corp OH, and Gantzert Investment Co. LLC ADV. Company insiders that have sold Amgen company stock in the last year include Cynthia M Patton, David Piacquad, David W Meline, Jonathan P Graham, R Sanders Williams, and Ronald D Sugar. View insider buying and selling activity for Amgen.

Which major investors are buying Amgen stock?

AMGN stock was purchased by a variety of institutional investors in the last quarter, including State of Alaska Department of Revenue, American National Bank, Birch Capital Management LLC, Orrstown Financial Services Inc., M&R Capital Management Inc., RDA Financial Network, and Fulton Bank N.A.. View insider buying and selling activity for Amgen.

How do I buy shares of Amgen?

Shares of AMGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Amgen's stock price today?

One share of AMGN stock can currently be purchased for approximately $211.58.

How big of a company is Amgen?

Amgen has a market capitalization of $124.79 billion and generates $23.36 billion in revenue each year. The medical research company earns $7.84 billion in net income (profit) each year or $14.82 on an earnings per share basis. Amgen employs 23,400 workers across the globe. View additional information about Amgen.

What is Amgen's official website?

The official website for Amgen is http://www.amgen.com/.

How can I contact Amgen?

Amgen's mailing address is ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA, 91320. The medical research company can be reached via phone at 805-447-1000 or via email at [email protected]

This page was last updated on 4/7/2020 by MarketBeat.com Staff

Featured Article: How Do Front-End Loads Impact an Investment?

NASDAQ:AMGNAmgen Stock Price, Forecast & News

Adding

Adding

Adding Amgen, Inc.

Beat the Market (BTM) Rank™

3.3 Analyst's Opinion

Consensus Rating

Price Target Upside/Downside

Amount of Analyst Coverage

3.0 Community Rank

Outperform Votes

Underperform Votes

Community Sentiment